Paolo Ghia, MD, PhD, discusses the CAPTIVATE trial in chronic lymphocytic leukemia/small lymphocytic lymphoma, and what ...

Ibrutinib, a BTK inhibitor, is effective in treating relapsed CLL, with combination therapies improving response rates. Combination therapy with ibrutinib and venetoclax, guided by MRD ...

Investigators found that lipid metabolism disruptions spark T-cell dysfunction in patients with chronic lymphocytic leukemia.

During a Case-Based Roundtable® event, Ryan W. Jacobs, MD, discussed a patient who received 2 prior lines of therapy for ...

"Patients with treatment-naive CLL have several treatment options ... undetectable measurable residual disease (MRD), and OS. Undetectable MRD, measured in peripheral blood, was highest in ...

and clinical outcomes have been shown to be strongly associated with MRD levels measured by clonoSEQ in patients diagnosed with CLL, MM, B-ALL and DLBCL. For important information about the FDA ...

For patients with relapsed/refractory chronic lymphocytic leukemia, extended treatment with Imbruvica and Venclexta was found ...

and clinical outcomes have been shown to be strongly associated with MRD levels measured by clonoSEQ in patients diagnosed with CLL, MM, B-ALL and DLBCL. Adaptive Biotechnologies ("we” or "our”) is a ...